⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Biomea Fusion to Participate in Upcoming Investor Conferences
globenewswire.com
BMEA
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
globenewswire.com
BMEA
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Exploring Innovations: Apple, Oura, Samsung, Fitbit, and Xiaomi's Pivotal Role in Smart Wearable Jewelry Evolution
globenewswire.com
AAPL
FOSL
GRMN
BMEA
XOM
Form 8-K
sec.gov
BMEA
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
globenewswire.com
BMEA
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
globenewswire.com
BMEA